Stockwinners Market Radar for November 30, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EST Cathie Wood's ARK Investment bought 39.2K shares of Crowdstrike today

18:45 EST Snowflake CEO: Overall, things are strong - In an interview on CNBC's Mad Money, Frank Slootman said for a company of Snowflake's scale to be growing at this rate is unprecedented. "The tailwinds we are experiencing in our business are enormous," he noted. "Customers are trying to accelerate and they want us to help them do it." Advertising is "red hot," and there is tremendous demand from that area, he added.

18:25 EST Salesforce CEO: Departure of co-CEO Bret Taylor 'a gut punch' - In an interview on CNBC's Mad Money, Marc Benioff said, "We do our best to bring up great talent, but sometimes they have to leave." He noted that the company is seeing "unprecedented" FX headwinds that were never anticipated. Salesforce closed a lot key transactions in the quarter. "We had big wins," he added.

18:15 EST Viracta reports Phase 1b/2 trial results for Nana-val in EBV+ tumors - Viracta Therapeutics reported preliminary dose-ranging data from the first two dose levels of the dose escalation part of the Phase 1b/2 study of Nana-val in patients with Epstein-Barr Virus-Positive - or EBV+ - recurrent/metastatic nasopharyngeal carcinoma - R/M NPC. The data are featured in an abstract accepted for a poster presentation at the European Society for Medical Oncology Immuno-Oncology Congress in Geneva, Switzerland, from December 7 - 9. The Phase 1b/2 trial's first two dose levels enrolled seven patients with EBV+ R/M NPC, six of whom were evaluable for response at the data cut-off date. Nana-val was well tolerated with no dose limiting toxicities reported. Most common Grade 1-2 AEs were fatigue, nausea, and increased creatinine. Two of six evaluable patients achieved stable disease. Plasma EBV DNA titers decreased or remained stable in both patients achieving SD, while rising in patients with progressive disease. The Phase 1b/2 trial is currently progressing through its third dose escalation cohort, with enrollment in the third dose level completed. Further safety data from the third dose level will be presented in the abstract's corresponding poster at ESMO-IO. The company anticipates initiating the Phase 2 randomized expansion portion of the Phase 1b/2 trial in the second half of 2023.

18:01 EST OncoCyte CEO Ronnie Andrews to step down, Joshua Riggs named interim CEO - Oncocyte announced that Ronnie Andrews will step down from his role as CEO and as a director of the company's board of directors effective December 1. In order to ensure a smooth transition effective as of December 2, Joshua Riggs will serve as interim CEO until such time as a new CEO has been identified and retained and Andrews will continue to act a consultant until February 28, 2023. Riggs, who has been Oncocyte's General Manager, Transplant since July 2022 and was the company's Senior Director Business Development from August 2020 until September 2022, is a seasoned business development strategist with significant experience working with early and growth-stage molecular diagnostics companies. From January 2016 to July 2020, he was a principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.

17:34 EST Shoals Technologies falls 9% to $26.24 after 20M share Class A stock offering

17:31 EST Advanced Merger Partners to redeem public shares and cancel business combination - Advanced Merger Partners will redeem all of its outstanding shares of Class A common stock, effective as of December 15, if stockholders approve a proposed amendment to its Amended and Restated Certificate of Incorporation and a proposed amendment to its investment management trust agreement dated March 1, 2021, with Continental Stock Transfer & Trust, at the special meeting to be held on December 14. There can be no assurance that the company's stockholders will approve the Early Termination Proposals and that the company will redeem the public shares. Currently, the company's Charter provides that it has until March 4, 2023 to complete its initial business combination and, if it does not complete an initial business combination by March 4, 2023, it will cease all operations except for the purpose of winding up, as promptly as possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders, and as promptly as reasonably possible following such redemption, liquidate and dissolve, subject in to applicable law. Holders of public shares may elect to redeem all or a portion of their public shares in exchange for their pro rata portion of the funds held in the trust account. The company expects to complete the Voluntary Redemption on or around December 14 if stockholders approve the Early Termination Proposals. The per-share redemption price for the public shares is expected to be approximately $10.08 on the Redemption Date. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless. The company expects that the last day of trading of its units and Class A common stock on the NYSE will be December 14, following which, the company expects that the NYSE will delist its securities on or about December 15.

17:27 EST Aerojet Rocketdyne awarded $239.68M Missile Defense Agency contract - Aerojet Rocketdyne was awarded a $239.68M modification to a previously awarded contract to exercise an option and award Medium Range Ballistic Missile Type 1/Type 2 Lot 3. The value of this contract is increased from $839.09M to $1.08B. Under this modification, the contractor will provide Option CLIN 0082 program management office support for calendar year 2023 and six launch vehicles and 6 Enhanced Solid Rocket-19 motors. The work will be performed in Orlando and Cape Canaveral Space Force Station, Florida. The performance period is from November 30, through October 31, 2029. FY23 research, development, test and evaluation funds in the amount of $7.9M are being obligated on this award. The Missile Defense Agency is the contracting activity.

17:10 EST Sturm Ruger declares special dividend of $5.00 per share - Dividend is effective for stockholders of record as of December 15, 2022, payable on January 5, 2023.

17:02 EST 180 Life Sciences updates on progress to seek medicines for RIDD - The company states: "180 Life Sciences announced that the Company and its regulatory consultants from the US and the UK, met with the UK Medicines and Healthcare products Regulatory Agency scientific advice committee for the second time on October 31, 2022. The Company provided additional data to MHRA concerning the use of nodule size and hardness as surrogate markers relating to eventual finger contraction in Dupuytren's disease, and raised a series of questions to MHRA. On November 23, 2022, the Company received formal written scientific advice regarding such matters. The MHRA reviewed the primary and secondary endpoints in the Repurposing Anti-TNF for Treating Dupuytren's Disease, RIDD, trial and the data provided by the Company. They noted that it has not been shown that reducing nodule size via treatment would lead to improvements in terms of disease progression, which the Company understands, and requested support for a correlation with clinical outcomes. The MHRA also asked for additional literature supporting the clinical safety of adalimumab from other approved indications such as rheumatoid arthritis. The Company plans to provide further information to the MHRA to address its comments."

17:00 EST OneConnect changing ADS ratio to 30 per ordinary share - OneConnect will change the ratio of its ADSs representing its ordinary shares from one ADS representing three ordinary shares to one ADS representing 30 ordinary shares. The ratio change will take effect at the open of trading of the NYSE on December 12, 2022. For OneConnect's ADS holders, the change in the ADS ratio will have the same effect as a one-for-ten reverse ADS split. There will be no change to the company's ordinary shares. ADSs outstanding on the effective date will need to be exchanged for new ADSs, with every 10 existing ADSs being cancelled in exchange for the issuance of one new ADS by the depositary bank as of the effective date for the Ratio Change. OneConnect's ADSs will continue to be traded on the NYSE under the symbol "OCFT". Fractional entitlements to new ADSs will be sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements will be distributed to the applicable ADS holders.

16:49 EST Atento CEO Carlos Lopez-Abadia to switch roles, Dimitrius Oliveira to succeed - Atento announced that its board of directors has appointed Dimitrius Oliveira as CEO and Anil Bhalla as executive chairman. Oliveira has also been appointed as a member of the board of directors of the company. Dimitrius previously was Atento's South America Regional Director. Dimitrius succeeds Carlos Lopez-Abadia who will continue working with Atento as an advisor. The company has appointed Anil Bhalla as executive chairman to lead strategic initiatives and specific growth objectives. Robert Payne will step down as chairman of the board of directors and continue to provide his support and guidance as non-executive director.

16:42 EST PVH Corp. jumps 9% to $73.38 after Q3 earnings beat, guidance raise

16:37 EST Salesforce falls 7% to $150 after Q3 results, resignation of co-CEO Bret Taylor

16:35 EST Conformis regains compliance with Nasdaq - Conformis announced that it received a letter from the Listing Qualifications Department of Nasdaq Stock Market notifying Conformis that, based on the closing bid price of Conformis' common stock having been $1.00 per share or greater on each of the trading days from November 10 to November 23, Conformis has regained compliance with Nasdaq Listing Rule 5550 and the minimum bid price deficiency matter previously disclosed by Conformis is now closed.

16:33 EST GSI Technology announces implementation of cost reduction initiatives - GSI Technology, announced the implementation of cost reduction initiatives to better align its operational structure with its near-term and long term goals for APU products currently under development.GSI aims to reduce its operating expenses by approximately $7.0 million on an annualized basis, primarily from salary reductions related to reduced headcount and salary decreases for certain retained employees, as well as targeted reductions in research and development spending. These strategic cost reduction measures are expected to enable GSI to better focus its operational resources on advancing its proprietary APU technology. "GSI's goal with these cost reduction initiatives is to scale our operations more appropriately and target investments more precisely to increase our efficiency," stated Lee-Lean Shu, GSI Technology Chairman and Chief Executive Officer. "The launch of Gemini-I and continued development of Gemini-II remain our primary priorities while supporting the essential operations of our legacy SRAM business, including our radiation-hardened and radiation-tolerant SRAM products." None of the Gemini-II chip development and core APU software development, including the APU compiler, will be affected by the reduction in R&D spending, and the APU marketing, sales, and APU engineering efforts will retain priority in the budget. The planned spending reductions will not impact the launch of Gemini-I in target markets, including SAR, search, and SaaS. The cost reduction initiative is expected to be completed by March 31, 2023 and will result in an approximate 15% decrease in GSI's global workforce. GSI expects to incur approximately $850,000 in termination costs, including the payout of accrued vacation, which will require cash expenditures, most of which are expected to be incurred in the current fiscal year.

16:32 EST Arcadia Biosciences CFO Pam Haley stepping down, Thomas Schaefer to succeed - Arcadia Biosciences CFO Pam Haley will be leaving the company and will be replaced by Thomas Schaefer, effective January 3, 2023. Schaefer is currently Arcadia's VP of finance and investor relations. Haley will remain in an advisory role to support the transition. Schaefer began his career as an equity research analyst and later joined a Fortune 500 company. He later served as director of finance at Flavor Producers, a portfolio company owned by private equity firm GTCR that specialized in beverages and snacks, before joining Arcadia in 2020.

16:31 EST Byline Bancorp, Inland Bancorp announce definitive merger agreement - Byline Bancorp and Inland Bancorp, Inc. jointly announced that they have entered into a definitive merger agreement pursuant to which Inland Bancorp and its wholly owned subsidiary, Inland Bank and Trust, will combine with Byline Bancorp, Inc. in a cash and stock transaction valued at approximately $165M based upon Byline's closing stock price as of November 29, 2022. The transaction will solidify Byline's position as Chicago's largest community bank with assets under $10B. It will also expand Byline's footprint into other attractive and contiguous suburban Chicago communities. The combined organization will have approximately $8.5B in assets, $6.2B in loans and $6.6B in deposits, with 47 branches across the greater Chicago metropolitan area. Inland Bancorp, Inc., the parent company of Inland Bank and Trust, is headquartered in Oak Brook, Illinois and had total assets of $1.2B, total loans of $854M and total deposits of $1B as of September 30, 2022. Serving its communities for over 40 years, Inland Bank and Trust offers commercial and retail banking services, with 10 branch locations primarily in the western and northern suburbs of Chicago. Roberto Herencia, Executive Chairman and Chief Executive Officer of Byline Bancorp, Inc., stated, "Inland Bank and Trust is a well-established and trusted financial institution with deep client and community relationships, which we look forward to continuing. Joining forces with Inland Bancorp brings to all of our customers an expanded footprint across Chicago. We are very excited to welcome Inland Bancorp customers and colleagues to Byline."

16:30 EST Nutanix reports A1 ACV up 27% y/y at $231.9M - Reports Q1 ARR up 34% y/y at $1.28B

16:26 EST Costco reports November revenue $19.17B, Q1 SSS up 6.6% - Costco 1Q SSS rose 6.6% . Reports Q1 revenue $53.44B, consensus $54.9B.

16:22 EST La-Z-Boy increases quarterly dividend 10% - The board declared a quarterly cash dividend of 18.15c per share on the common stock of the company, an increase of 10% over the prior quarter. The dividend will be paid on December 20, 2022, to shareholders of record on December 12, 2022.

16:20 EST General Electric board approves separation of GE HealthCare - General Electric announced that its board of directors has approved the previously announced spin-off of its healthcare business, GE Healthcare Holding LLC. Prior to such spin-off, GE HealthCare is expected to be converted into a corporation and renamed GE HealthCare Technologies Inc. The company is expected to begin trading on Nasdaq on January 4, 2023, under the ticker "GEHC."

16:18 EST General Electric board approves separation of GE HealthCare - General Electric "announced that its Board of Directors has approved the previously announced spin-off of its healthcare business, GE Healthcare Holding LLC. Prior to such spin-off, GE HealthCare is expected to be converted into a corporation and renamed GE HealthCare Technologies Inc. The company is expected to begin trading on Nasdaq on January 4, 2023, under the ticker 'GEHC'."

16:16 EST Amtech Systems announces 'large repeat order' for EV modules - Amtech Systems "announced the receipt of an order for 20 controlled atmosphere furnaces for production of Direct Bond Copper substrates. The repeat order was received by Amtech division, BTU International, for 20 controlled atmosphere furnaces for delivery starting in the second half of fiscal 2023. These continuous furnaces will be used for the volume production of DBC substrates, a process which requires extreme control of thermal uniformity and oxidation atmosphere. The furnaces will be produced at BTU's factory in the USA and shipped to customer locations in Asia. The DBC substrates produced by these furnaces will be used for power device modules intended for electric vehicles".

16:10 EST Shoals Technologies CEO Jason Whitaker to step down - Shoals Technologies announced that its CEO, Jason Whitaker, has informed the board of directors that he intends to step down from his role as CEO for health reasons in early 2023. Whitaker will remain with the company in an advisory role until mid-March 2023. Brad Forth, chairman of the board of Shoals, is leading the board search for a new CEO, with the assistance of executive search firm Spencer Stuart. Whitaker expects to continue serving on the board during this transition period.

16:09 EST Salesforce's Bret Taylor to step down as Vice Chair and co-CEO - Salesforce "announced that Bret Taylor will step down as Vice Chair and Co-CEO of Salesforce, effective January 31, 2023. At that point, Marc Benioff will be Chair and CEO of the company."

16:08 EST Five Below sees FY22 comparable sales down 2%-3%

16:08 EST Five Below sees Q4 comparable sales down 1% to up 1%

16:05 EST Bank of New Zealand selects nCino Bank Operating System as key platform - nCino announced that the Bank of New Zealand or BNZ, has selected the nCino Bank Operating System as a key technology platform. nCino's single cloud-based platform enables financial institutions to more effectively onboard clients, make loans, manage loan life cycles, and open deposit and other accounts across lines of business and banking channels. Mark Bernhardi, Managing Director of Australia, and New Zealand at nCino says, "Now, more than ever, financial institutions require an end-to-end digital and customer-centric platform approach in order to meet the increasing and changing expectations of their customers at speed. We look forward to partnering with BNZ on this journey." With more than $100B NZD in assets or $56.2B, BNZ has operated in New Zealand since opening its first office in Auckland in October 1861. The bank employs over 5,000 people in New Zealand. BNZ Executive Customer, Products, and Services, Karna Luke says, "Our customers have high expectations, and BNZ is continually seeking improvements to our exceptional customer experience delivery through careful investment in digital capabilities and operational excellence."

16:02 EST Bentley Systems' Cohesive Group acquires Vetasi - Bentley Systems announced that its Cohesive Group digital integrator business has acquired Vetasi, a leading international consultancy specializing in enterprise asset management solutions, with a strong focus on IBM Maximo. The company states that "Vetasi brings to Cohesive the largest IBM Maximo consultancy team across Europe, Africa, and ASEAN countries, with headquarters in the United Kingdom and operations based in Poland, Indonesia, South Africa, Spain, Ukraine, and Australia. In addition to EAM resources, Vetasi deepens the Cohesive team with additional strategic advisory capabilities and adds to the Cohesive services catalog Maximo cloud hosting capabilities, expertise in low-code development, and strong real estate and facilities management domain knowledge. By virtue of the combination with Cohesive, Vetasi's clients can benefit from the multidiscipline scope of a world-leading digital integrator, combining greater global scale with local agility to leverage more value from their asset portfolios."

15:30 EST FDA announces bebtelovimab not currently authorized in any U.S. region - The FDA announced that bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. "Given that a COVID-19 infection is likely to be caused by a non-susceptible SARS-CoV-2 variant, and consistent with the terms and conditions of the Letter of Authorization, bebtelovimab is not currently authorized for emergency use in any U.S. region at this time," the FDA stated. Eli Lilly and its authorized distributors have paused commercial distribution of bebtelovimab until further notice by the Agency, the FDA stated. The U.S. Government recommends all product be retained in the event that SARS-CoV-2 variants susceptible to bebtelovimab, which are currently circulating at lower prevalence, become more prevalent in the future in the United States, the Agency added. Reference Link

15:16 EST Gorilla Technology Group Inc trading halted, volatility trading pause

14:51 EST AbCellera down 7% after FDA announces bebtelovimab not authorized in U.S. - Shares of AbCellera (ABCL) are down 87c, or 7%, to $12.49 after the FDA announced that bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. Eli Lilly (LLY) and its authorized distributors have paused commercial distribution of bebtelovimab until further notice by the Agency, the FDA stated.

14:45 EST Ennis acquires School Photo Marketing, terms not disclosed - Ennis announced its acquisition of School Photo Marketing in Morganville, New Jersey. School Photo Marketing provides printing, yearbook publishing and marketing-related services to over 1,400 school and sports photographers servicing schools around the country. Keith Walters, Chairman, President & CEO of the Company stated, "We are delighted to have the opportunity to bring School Photo Marketing, their employees, and their customers into the Ennis family. This addition brings with it many exciting possibilities to service this new channel with products produced through Ennis manufacturing operations." Upon closing, operations will continue to operate as School Photo Marketing in their current locations.

14:21 EST AWS announces new Amazon SageMaker capabilities - At AWS re:Invent, Amazon Web Services, an Amazon.com company, announced eight new capabilities for Amazon SageMaker, its end-to-end machine learning service. "Developers, data scientists, and business analysts use Amazon SageMaker to build, train, and deploy ML models quickly and easily using its fully managed infrastructure, tools, and workflows. As customers continue to innovate using ML, they are creating more models than ever before and need advanced capabilities to efficiently manage model development, usage, and performance. Today's announcement includes new Amazon SageMaker governance capabilities that provide visibility into model performance throughout the ML lifecycle. New Amazon SageMaker Studio Notebook capabilities provide an enhanced notebook experience that enables customers to inspect and address data-quality issues in just a few clicks, facilitate real-time collaboration across data science teams, and accelerate the process of going from experimentation to production by converting notebook code into automated jobs. Finally, new capabilities within Amazon SageMaker automate model validation and make it easier to work with geospatial data," AWS stated.

13:08 EST North American rail traffic up 2.4% for the week ending November 26 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending November 26. For this week, total U.S. weekly rail traffic was 413,305 carloads and intermodal units, down 4.1% compared with the same week last year. Total carloads for the week ending November 26 were 206,792 carloads, down 1.1% compared with the same week in 2021, while U.S. weekly intermodal volume was 206,513 containers and trailers, down 6.9% compared to 2021. Four of the 10 carload commodity groups posted an increase compared with the same week in 2021.They included miscellaneous carloads, up 4,015 carloads, to 10,410; motor vehicles and parts, up 1,516 carloads, to 12,199; and metallic ores and metals, up 299 carloads, to 18,552. Commodity groups that posted decreases compared with the same week in 2021 included grain, down 3,354 carloads, to 20,261; coal, down 2,211 carloads, to 61,740; and chemicals, down 1,854 carloads, to 28,184. North American rail volume for the week ending November 26, on 12 reporting U.S., Canadian and Mexican railroads totaled 311,026 carloads, up 4.4% compared with the same week last year, and 283,638 intermodal units, up 0.3% compared with last year. Total combined weekly rail traffic in North America was 594,664 carloads and intermodal units, up 2.4%. . North American rail volume for the first 47 weeks of 2022 was 31,825,338 carloads and intermodal units, down 1.9% compared with 2021. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), FreightCar America (RAIL), Trinity Industries (TRN), Greenbrier (GBX) and Wabtec (WAB). Reference Link

12:57 EST Twitter says transparent approach to platform changes 'healthy' - Twitter said in a blog post that it is a "new company embarking on a new chapter," calling the new strategy under owner Elon Musk "Twitter 2.0." "As you've seen over the past several weeks, Twitter is embracing public testing," the post reads. "We believe that this open and transparent approach to innovation is healthy, as it enables us to move faster and gather user feedback in real-time. We believe that a service of this importance will benefit from feedback at scale, and that there is value in being open about our experiments and what we are learning. We do all of this work with one goal in mind: to improve Twitter for our customers, partners, and the people who use it across the world." "As we carry out this work, we want to assure you of a few things: First, none of our policies have changed. Our approach to policy enforcement will rely more heavily on de-amplification of violative content: freedom of speech, but not freedom of reach," the company added. "Our Trust & Safety team continues its diligent work to keep the platform safe from hateful conduct, abusive behavior, and any violation of Twitter's rules. The team remains strong and well-resourced, and automated detection plays an increasingly important role in eliminating abuse. When urgent events manifest on the platform, we ensure that all content moderators have the guidance they need to find and address violative content. As we improve our policies and processes, bad actors will also develop new methods of disruption. This is not new. Our team of experts is constantly adapting to identify and defuse threats, and we are proud of our early results: impressions on violative content are down over the past month, despite the growth in overall usage on the platform. Finally, as we embark on this new journey, we will make mistakes, we will learn, and we will also get things right. Throughout, we'll communicate openly with our users and customers, to get and share your feedback as we build." Reference Link

12:50 EST Coinbase Wallet to stop supporting BCH, ETC, XLM, XRP - Coinbase said on Tuesday that it will delist XRP, Bitcoin Cash, and Ethereum Classic from its crypto wallet. Coinbase said that the cryptocurrencies would no longer be supported on Coinbase Wallet starting in January "due to low usage," but users still can withdraw any unsupported assets by using their wallet recovery phrase. Reference Link

12:00 EST SentinelOne falls -10.9% - SentinelOne is down -10.9%, or -$1.68 to $13.77.

12:00 EST iStar falls -23.0% - iStar is down -23.0%, or -$2.28 to $7.62.

12:00 EST Nio rises 17.1% - Nio is up 17.1%, or $1.80 to $12.30.

11:55 EST Aerojet Rocketdyne trading resumes

11:34 EST Radius Global Infrastructure trading resumes

11:24 EST Radius Global Infrastructure trading halted, volatility trading pause

10:40 EST TV MIDTVEST expands strategic relationship with Avid Technology - Danish regional broadcaster TV MIDTVEST has extended its strategic relationship with Avid by transitioning onto Avid's MediaCentral Flex subscription software.

10:28 EST Charles River trading resumes

10:21 EST Global Tech retains Christian Levine to investigate possible naked short selling - Global Tech Industries Group announced that its board of directors approved and instructed management to negotiate and execute a service agreement with The Christian Levine Law Group, as well as Warshaw Burstein, LLP, to review the trading history of the Company's common stock for the past two years. The Company believes it may have been the target of a market manipulation scheme involving naked short selling of its common stock. According to various publicly disclosed sources, these two firms, during the past 22 years, have successfully prosecuted and collected millions of dollars in aggregate damages on behalf of their clients from broker-dealers, market-makers, hedge funds, and asset-based lenders who have engaged in such market manipulation schemes.

10:14 EST Endurance Acquisition Corp trading resumes

10:04 EST Booking Holdings expands Travel Sustainable program across brands - Booking Holdings announced the expansion of its Travel Sustainable program to relevant brands across the Booking Holdings family. The news marks the company's delivery on its commitment to launch its first-of-its-kind program for accommodations enterprise-wide by the end of 2023. Travel Sustainable provides credible information on impactful sustainability efforts taken by properties worldwide and gives travelers a transparent, consistent and easy-to-understand way to identify a wider range of more sustainable stays, no matter where they want to travel. The aim of the program is to give visibility to accommodations that have made progress on a broad spectrum of sustainability efforts, from those at an earlier stage to those who have achieved one of more than 40 recognized ecolabels and certifications through outstanding commitments and investments. Pioneered by Booking.com, which recently marked the one year anniversary of the program, there are now more than 400,000 accommodations recognized globally by the Travel Sustainable program. Recognized properties across Priceline, Agoda and KAYAK will now feature the Travel Sustainable badge in search results, with some platforms also implementing an additional filter to help travelers book more sustainable accommodations.

10:04 EST Charles River says not named or referenced in DOJ proceedings - In a regulatory filing, Charles River said that during its presentation at Evercore ISI 5th Annual HealthCONx Conference, management will address the topic of non-human primate supply following the November 16, 2022 announcement by the U.S. Department of Justice through the U.S. Attorney's Office for the Southern District of Florida that a Cambodian NHP supplier and two Cambodian officials had been criminally charged in connection with illegally importing NHPs into the U.S. "In particular, in recognition of the numerous investment analyst and media reports related to NHP pricing, the NHP supply chain, and the DOJ proceedings, the Company made statements to the following effect: a.Charles River was not named or referenced in the DOJ proceedings, and the Company does not have any direct supply contracts with the indicted Cambodian supplier. b.Charles River has global supply sources, including other sources in Cambodia, which is the primary country of origin of NHP imports to the United States and to Charles River. However, in light of the indictment, and subsequent statements made by the Cambodia government, Charles River is operating under the expectation that for some time period supply of Cambodia-sourced NHPs will be difficult to obtain in the United States; and c.The Company is diligently working to mitigate any Cambodia NHP supply impact with ongoing efforts to procure NHPs under different supply arrangements and from other global sources."

10:01 EST Q2 Holdings helps Johnson Financial modernize digital banking experience - Q2 Holdings announced it has helped Johnson Financial Group transform its digital banking experience for its banking, wealth and insurance customers. JFG can now provide a personalized "one-stop-shop" experience for its clients, offering a vast continuum of financial services through its mobile and online banking application.

10:00 EST SentinelOne falls -12.5% - SentinelOne is down -12.5%, or -$1.93 to $13.52.

10:00 EST Dingdong rises 14.8% - Dingdong is up 14.8%, or 57c to $4.46.

10:00 EST XPeng rises 24.8% - XPeng is up 24.8%, or $1.82 to $9.16.

09:47 EST CordovaCann partners with Jackson BevCo to open cannabis stores - CordovaCann announced that on November 29th the Company has entered into a non-binding letter of intent with Jackson BevCo to execute a managed services agreement to facilitate the opening and operation of cannabis retail stores within or beside convenience stores owned and operated by Jacksons. Jacksons owns and operates 65 convenience stores in the western United States under the Big Smoke and Tobacco Connection brand names. Jacksons is wholly-owned by Jacksons Food Stores, which was founded in 1975 as a single service station and has grown to be a nationally recognized chain with 361 wholly-owned convenience stores and is a joint-venture partner in nearly 2,000 additional convenience stores. Jacksons stores are predominantly located in Washington, Oregon, California, Arizona and Idaho. Pursuant to the terms of the LOI, Cordova will facilitate the opening of cannabis retail stores in all aspects requested by Jacksons, but with primary focus on regulatory process, compliance, training, security, inventory selection and inventory procurement. The cannabis retail stores opened under the MSA will be owned and operated by Jacksons, and Jacksons will pay Cordova a royalty based on a percentage of revenues generated by these cannabis retail stores. Cordova and Jacksons expect to have the MSA executed by January 2023. Cordova expects to launch the first cannabis retail stores within the Jacksons footprint in 2023. The initial locations currently being discussed by Cordova and Jacksons are in Washington, Oregon and Arizona. Given that Jacksons already has ideal convenience real estate in its existing locations, it is expected that the stores launched under the MSA will generate substantial revenue and profits from cannabis. Cordova already operates in key states where Jacksons is operating stores and recreational cannabis sales are legal. Cordova will be able to sell cannabis flower and manufactured products to stores opened under the MSA, which is expected to create another significant revenue stream beyond the royalty payments received.

09:47 EST SentinelOne falls -9.2% - SentinelOne is down -9.2%, or -$1.42 to $14.03.

09:47 EST Nio rises 12.6% - Nio is up 12.6%, or $1.32 to $11.82.

09:47 EST XPeng rises 24.3% - XPeng is up 24.3%, or $1.78 to $9.12.

09:38 EST Kintara Therapeutics Inc trading resumes

09:35 EST NetApp trading resumes

09:33 EST Kintara Therapeutics Inc trading halted, volatility trading pause

09:26 EST TD Bank invests $5M in Citizens Trust Bank - The Commercial Bank of TD Bank announced that it has made a $5M equity investment in Citizens Trust Bank in Atlanta, Ga., to help expand opportunities for minority-owned businesses as it eyes further expansion into the region.

09:26 EST Performance Shipping completes sale, delivery of M/T P. Fos - Performance Shipping announced that, through a separate wholly-owned subsidiary, it has completed the previously announced sale of the 2007-built Aframax tanker vessel M/T P. Fos, with the delivery of the vessel to her new owners. Following the sale of the P. Fos, the Company's fleet currently consists of six Aframax tankers, with two more Aframax tankers expected to be delivered within December 2022.

09:22 EST Edible Garden to display product lines at 2022 New York Produce Show - Edible Garden announces that it will exhibit its expanding line of world-class, certified organic potted herbs, organic cut herbs, hydroponic basil, and local hydroponic lettuces, as well as highlight its Zero-Waste Inspired initiatives, at the 2022 New York Produce Show and Conference, booth #328, in New York City on Thursday, December 1, 2022. The New York Produce Show and Conference, a world-class event for the industry is presented by the Eastern Produce Council and PRODUCE BUSINESS Magazine. The highlight of the event is a one-day trade show on December 1st of more than 400 companies, providing producers and retailers the opportunity to network, build relationships and conduct business.

09:20 EST Surna awarded third contract with cultivation facility in Massachusetts - Surna signed its third consecutive contract with a Northeast cultivation facility. "We are pleased to announce a signed contract for $1.7 million with a large cultivation facility in Massachusetts," said Jon Kozlowski, Surna's Vice President of Sales. "Earlier this year, we performed mechanical engineering services for this 36,000 square feet of cultivation and processing space, followed by a benching contract. As we have consistently delivered on time and on budget, the client has continued to contract with us in each phase of their build-out." Surna was selected by the client based on Surna's expertise in cultivation facility design and equipment options. The first contract provided mechanical engineering design services that included professional engineer stamped drawings. The second contract earlier this year was for benching equipment, including installation, with a value of $615,000. This most recent contract includes HVACD equipment for the flower, veg, mother, clone, and dry/cure rooms, as well as cannabis processing rooms including extraction, packaging, production kitchen and trim room spaces. As part of the HVACD equipment order, Surna is providing its EnviroPro air handlers, IsoStream fan coils, Surna by Anden dehumidifiers and humidifiers, dry coolers, chillers, and airflow equipment.

09:17 EST Jamf Holding announces new integration with AWS - Jamf (JAMF) announced a new integration with Amazon Web Services (AMZN) to empower organizations using AWS and Jamf to elevate their security posture. AWS Verified Access allows customers to define a set of policies or criteria in Jamf that must be met before allowing end users and their respective devices to gain access to internal services on AWS.

09:12 EST Philips in research deal with MagCorp to explore magnets for MR scanners - Royal Philips entered into a research partnership with U.S. magnet solutions provider MagCorp to explore superconducting magnets for MR scanners that do not require cooling to ultra-low temperatures,-452 degrees F or -269 degrees C, using liquid helium. Developing more sustainable alternatives to helium-cooled MRI magnets at a lower cost has the potential to offer significant benefits by making advanced MR imaging available to more patients in more diverse settings as well as potentially reducing radiology department capital and operating costs. "Florida State University's MagLab, part of the U.S. National High Magnetic Field Laboratory, is home to many of the world's leading researchers on novel superconducting materials that don't require liquid helium temperatures to operate. Philips has decades of MR scanner design and development experience, including most recently the launch of the BlueSeal magnet technology," said Josh Hilderbrand, Director, Head of MRI Magnet Research and Development at Philips. "Combining these resources with MagCorp's research facilitation services will help leverage the latest technology to accelerate access and availability of MRI to more patients and healthcare providers."

09:12 EST Koil Energy annnounces ticker symbol change - Koil Energy Solutions, formerly known as Deep Down, announced that the Financial Industry Regulatory Authority has approved its application to change the company's name and ticker symbol, reflecting their new name and commitment to Energizing the Future. As of November 28, 2022, the ticker symbol for Koil has changed from "DPDW" to "KLNG" and can be searched as such.

09:11 EST Charles River Associates acquires bioStrategies Group - Charles River Associates announced its acquisition of bioStrategies Group, a Chicago-based consulting firm focused on developing commercial strategies for healthcare products and technologies. Under the terms of the transaction, which closed on November 29, CRA purchased substantially all of the assets of bioStrategies Group and retained the services of 17 employees, including Mike Kaestle and Chris Schneider, who have joined CRA's Life Sciences Practice as vice presidents.

09:10 EST Medigus regains compliance with Nasdaq minimum closing bid price rule - Medigu reported the receipt of a formal notification from The Nasdaq Stock Market hat the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ADSs to maintain a minimum bid price of $1.00 per ADS. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ADSs was at $1.00 per ADS or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.

09:09 EST Engine Capital sends letter to Univar board requesting initiation of review - Engine Capital, which owns approximately 1% of Univar Solutions Inc.'s shares, announced that it has sent the below letter to the members of the company's board of directors. "Engine Capital LP (together with its affiliates, "Engine" or "we") is a meaningful shareholder of Univar Solutions Inc. ("Univar" or the "Company"), with an ownership position of approximately 1% of the Company's outstanding shares. As you will recall, we sent you a letter in early October to highlight that the Company has been trading at a significant discount to its intrinsic value and encourage the Board of Directors (the "Board") to capitalize on this apparent mispricing by immediately initiating an aggressive share repurchase program. We also recommended that the Board initiate a review of strategic alternatives at the appropriate time. We applaud you for announcing a $200 million accelerated share repurchase and an additional $1 billion share repurchase authorization when Univar posted its Q3 results on November 1, 2022. We were also pleased to learn over the weekend that Univar has received a preliminary indication of interest from Brenntag SE ("Brenntag"). This strategic approach from a direct competitor confirms Engine's view that Univar is undervalued in the public market and, in turn, a highly attractive acquisition target for qualified buyers. Both Univar and Brenntag have now publicly confirmed the discussions, meaning Univar is effectively in play. As such, we urge you to publicly announce a competitive and formal sale process that invites additional parties to bid for the Company and ensures the Board has all the information needed to make a value-maximizing decision that benefits all shareholders. While we acknowledge the industrial logic of a combination between Univar and Brenntag, and believe the synergies would be material, we also note that private equity has been actively involved in the space, including through past ownership of both Univar and Brenntag. Our prior letter listed many precedent transactions that point to a transaction multiple for Univar between 9x and 10x 2023 Adjusted EBITDA. Based on analysts' estimates of $920 million 2023 Adjusted EBITDA, this multiple range would deliver a purchase price for shareholders between approximately $38 and $44 per share. We believe a sale price in that range is achievable if the Board runs a competitive sale process. It is our view that the stars have now aligned for Univar to run such a process, and we urge the Board to fulfill its fiduciary obligations and work to maximize value for all of the Company's shareholders."

09:09 EST Personalis and UCSF to study utility of ctDNA for treatment response in CRC - Personalis announced a collaboration with UC San Francisco UCSF that will deploy a personalized liquid biopsy-based research use only or RUO assay for a study of patients with colorectal cancer. The research efforts will use Personalis' NeXT Personal(TM) assay to evaluate circulating tumor DNA or ctDNA-based signatures associated with treatment response and adverse events in a cohort of late-stage colorectal cancer patients receiving capecitabine together with pembrolizumab and bevacizumab. Colorectal cancer is among the top five most prevalent and deadly malignancies worldwide. The efficacy of combined targeted therapy approaches varies widely, reflecting the need for more sophisticated predictive measures. Typical ctDNA assays in use today lack sufficient sensitivity for detecting cfDNA-based biomarkers due to extensive disease heterogeneity, potentially low levels of signal from small metastases, and the wide range of mutational profiles relevant to different types of cancer.

09:08 EST Aeglea: Jim Kastenmayer to retain position as general counsel - Jim Kastenmayer, JD, PhD, will step down as interim CEO and retain his position as Aeglea's general counsel. "On behalf of the entire board of directors, I want to thank Jim for his service and commitment to Aeglea and its mission. Jim has provided exceptional leadership during a period of critical execution and has kept the team focused on advancing the Homocystinuria program," said the company.

09:07 EST Aeglea no longer plans to announce Phase 1/2 pegarviliase data in Q4 - Following the leadership transition and as part of the related evaluation of near-term corporate and clinical development strategy, Aeglea no longer plans to announce interim clinical data from the ongoing Phase 1/2 clinical trial of pegtarviliase in Classical Homocystinuria in the fourth quarter of 2022. Enrollment in the third cohort of the Phase 1/2 trial is ongoing with two patients having completed dosing in the cohort. Additionally, the company has decided not to participate in the Piper Sandler 34th Annual Healthcare Conference and 5th Annual Evercore ISI HealthCONx Conference, both being held November 29-December 1, 2022. Aeglea said it looks forward to delivering a clinical update on the pegtarviliase program when more comprehensive data from the third cohort becomes available.

09:06 EST Wolters Kluwer completes divestment of legal information units in France, Spain - Wolters Kluwer Legal & Regulatory announces that it has completed the divestment of its legal information units in France and Spain to Karnov, as originally announced on December 9, 2021.

09:05 EST GitLab launches GitLab Dedicated solution - GitLab announced the limited availability of GitLab Dedicated, a new way to use GitLab - as a single-tenant software as a service solution. The new offering will provide all the benefits of an enterprise DevSecOps platform with a focus on data residency, isolation, and private networking to meet complex compliance needs. Additionally, users can leverage the efficiency of the cloud while working in an isolated instance, and remove the overhead of platform and infrastructure management.

09:04 EST Marvell extends collaboration with Nokia - Marvell Technology (MRVL) announced an extension of its collaboration with Nokia (NOK) that further advances Nokia's 5G "Powered by ReefShark" chipset portfolio. The companies have worked closely on the new OCTEON 10 Data Processing Unit, or DPU, which augments the ReefShark family with best-in-class 5G transport built on cutting-edge 5nm processor and hardware acceleration technology. The jointly developed solution equips mobile network operators with the ability to rapidly evolve their networks and deliver innovative new 5G services at high performance and capacity with ultra-low latency and energy efficiency.

09:03 EST LPL Financial appoints Adam Turnquist as Chief Technical Strategist - LPL Financial (LPLA) announced the appointment of Adam Turnquist as Chief Technical Strategist for the firm's Investment Research team. In his new role Turnquist will lead the firm's technical analysis of global capital markets. He will also serve as a key member of the firm's Strategic and Tactical Asset Allocation Committee. Turnquist will report to LPL's Chief Investment Officer, Marc Zabicki. Prior to joining LPL he served as Vice President on Piper Sandler's (PIPR) research team, and has worked as a fixed income trader.

09:02 EST Electromed receives FDA clearance for SmartVest Clearway Airway Clearance System - Electromed announced that it received FDA 510(k) clearance of the SmartVest Clearway Airway Clearance System, which is designed for High Frequency Chest Wall Oscillation, or HFCWO, therapy. The SmartVest Clearway system, an updated and modern approach to HFCWO, offers an enhanced patient experience with proven patient outcomes.

09:01 EST Vinci Retirement Services announces insurer approval by SUSEP - Vinci Partners Investments announced that the Vinci Retirement Services segment has been approved, formally through its invested company Vinci Vida e Previdencia S/A, to operate life insurance and open-ended pension plans in Brazil by SUSEP, the Brazilian superintendency for private insurance. VRS is the new initiative from Vinci Partners, which began structuring in 2022, and has since been disclosed as a separate and new business segment. VRS will work to provide pension planning solutions to investors through robust and efficient technological tools, alongside alternative distribution vehicles.

08:55 EST Rubicon Technologies signs extended waste diversion agreement with Sweetgreen - Rubicon Technologies (RBT) announced that it has signed an extended, three-year agreement with Sweetgreen, (SG) to continue to help expand sweetgreen's waste diversion efforts, and provide enhanced account management as the company's lead partner for waste, recycling, and composting services. Sweetgreen has been working with Rubicon since 2016.

08:47 EST Grid Dynamics inaugurates first engineering center in Hyderabad - Grid Dynamics Holdings announced the official opening of its new office in Hyderabad. The expansion to India plays a critical role in Grid Dynamics' growth and positioning by further enabling the company to scale its engineering workforce, support clients, and accelerate its expansion as a leading global technology services provider. The new office is one of its three strategic locations to support the company's global expansion, along with operational centers in Poland, Mexico, and other global locations. The India Engineering Center is critical to strengthening shareholder value and Grid Dynamics' strategic blueprint as a global engineering and technology company. Within the next year, Grid Dynamics will continue expanding its engineering team in India, where they plan to house a significant part of its global workforce. Having a presence in Hyderabad is another step toward achieving strategic growth plans to provide a global delivery footprint to support clients. Many of Grid Dynamics' Fortune 100 clients from North America and Europe have operations in India. Grid Dynamics' presence there will further enable the company to provide its customers with the highest quality of talent at the required scale and support its expansion powered by both organic and inorganic growth through mergers and acquisitions.

08:45 EST Runway Growth Finance commences offering of notes - Runway Growth Finance announced that it has commenced an underwritten offering of unsecured notes, subject to market and other conditions. The Company has applied for the Notes to be listed and trade on the Nasdaq Global Select Market. If approved for listing, the Company expects the Notes to begin trading within 30 days from the original issue date. The interest rate and other terms of the Notes will be determined at the time of pricing of the offering. The Company intends to use the net proceeds from this offering to repay outstanding indebtedness under its Credit Agreement with KeyBank National Association. However, through re-borrowing of the initial repayments under the Credit Facility, the Company intends to use the net proceeds from this offering to make investments in accordance with its investment objective and strategies described in the prospectus supplement and the accompanying prospectus, to pay operating expenses and other cash obligations, and for general corporate purposes. As of November 28, 2022, the Company had $365.0 million of indebtedness outstanding under the Credit Facility, which bore interest at a rate of 6.659% as of such date. The Credit Facility matures on April 20, 2026. Oppenheimer & Co. Inc., UBS Securities LLC, B. Riley Securities, Inc. and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers of this offering. Compass Point Research & Trading, LLC, Janney Montgomery Scott LLC and Hovde Group, LLC are acting as co-managers of this offering.

08:42 EST Forum Energy generates approximately $32M from sale-leaseback transaction - Forum Energy Technologies announced that it has closed a sale of four manufacturing and distribution centers located in Texas and Louisiana. The properties will remain an integral part of FET's operations strategy going forward. In connection with the sale, the Company entered into a long-term lease agreement. The net sales proceeds from the transaction totaled approximately $32M. Neal Lux, President and Chief Executive Officer, remarked, "This transaction generates value for our stakeholders at an EBITDA multiple over ten times future annual lease payments. These sale proceeds and our projected second half 2022 free cash flow represent a $60 to $70M net debt reduction since June 30. Our capital light business model provides significant flexibility to use the sale proceeds and free cash flow generated to improve our balance sheet and fund growth opportunities."

08:39 EST FuboTV, SMAC Productions to co-produce eight part football documentary - SMAC Productions, a division of SMAC Entertainment, creator of scripted and non-scripted content, and Fubo Studios, the original production arm of FuboTV, have announced plans to co-produce an eight-part documentary series on the evolution of the Black quarterback in America. Through a series of conversations with former and current players and coaches, cultural figures, celebrities and journalists, all led by Michael Vick - the series will examine how on-field commanders changed the game and led off-field movements.

08:38 EST Phunware launches initiative to give back control of consumer data - Phunware announced it intends to give control of data currently stored by the Company back to consumers in an ongoing effort to commercialize a new data economy that leverages blockchain to reimagine how brands engage consumers. By most accounts, data is now the most valuable asset in the world. Phunware has gathered over a petabyte of data from billions of devices with the intention of creating a Phunware ID for every human being on the planet with a mobile device touching a network. To better manage consent and ensure fair compensation for first-party data, Phunware will enable consumers to identify and manage data being curated within the Phunware Knowledge Graph. Phunware intends to compensate consumers in PhunCoin for use of their data and increasing the value of the ecosystem, while rewarding them in PhunToken for generating additional data through brand engagement.

08:37 EST Tantech Holdings subsidiary receives second order from Nigeria for 6 midibuses - Tantech Holdings announced that its subsidiary, Shangchi Automobile had received a second order from Nigeria to export 6 additional fully customized midibuses within 60 days. Tantech has successfully integrated several innovations with solid track records into vehicle design and craftsmanship. Both vehicle power and energy efficiency have been significantly improved, largely by adopting a more robust engine with embedded advanced technologies.

08:36 EST Recon Technology awarded $940,000 two year contract - Recon Technology announced that Nanjing Recon Technology Co. has been awarded an approximately $940,000 two-year contract to provide automation control and instrumentation maintenance services for a gas generation plant operated by a top mainland China's oil and gas company. The contract involves both fixed maintenance fees and variable expenses on component replacement fees. Recon will also be in charge of repair works and provide emergency troubleshooting across platforms and channels to ensure smooth data transfer, power supply and stable remote connection on the production site.

08:35 EST Bel Fuse appoints Kozlovsky as Global Head of People - Bel Fuse announced Suzanne Kozlovsky has been appointed as Global Head of People. In this newly created executive level position, Kozlovsky will initially be focused on a series of initiatives around associate engagement, development, talent retention strategies and compensation structure. Prior to her appointment by Bel, Kozlovsky was Vice President of Human Resources for Prinova where she was a core member of the Global Executive Council and Strategy and Investment Team.

08:35 EST Global Water Resources raises monthly cash dividend 1% to 2.483c per share - Global Water Resources has declared, under its dividend policy, a monthly cash dividend increase of 1% to 29.791c on an annualized basis. This equates to a monthly dividend of 2.483c. The first dividend at the new monthly rate will be paid on December 29, 2022, to holders of record at the close of business on December 15, 2022.

08:33 EST Scynexis announces $3M NIH grant awarded to study fungerp - SCYNEXIS announced that researchers from Case Western Reserve University in Cleveland have been awarded a competitive research grant of more than $3M by the National Institutes of Health, NIH, to investigate a second generation fungerp developed by SCYNEXIS as a potential treatment for Candida auris (C.auris), a multidrug-resistant yeast that causes serious and often deadly infections. The five-year grant from the National Institute of Allergy and Infectious Diseases of NIH will allow the team led by researchers at the Case Western Reserve School of Medicine and University Hospitals Cleveland Medical Center to evaluate this novel antifungal drug developed by SCYNEXIS. The research team will be led by Mahmoud Ghannoum, Ph.D. "It is thrilling to see the NIH fund this important research to investigate oral and IV SCY-247, one of our patented triterpenoid antifungals, to target drug resistant C. auris, where there is great need due to limited treatment options and the potential to save lives," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "We congratulate Dr. Ghannoum on receiving this grant and want to express our gratitude for his ongoing commitment to patients suffering from terrible and deadly fungal infections."

08:33 EST Corning unveils Corning Gorilla Glass Victus 2 - Corning Incorporated unveiled its newest glass innovation, Corning Gorilla Glass Victus 2. Corning continues to push the boundaries of glass by expanding its Corning Gorilla Glass portfolio. With a new glass composition, Gorilla Glass Victus 2 delivers improved drop performance on rough surfaces like concrete, the world's most abundantly engineered material, while preserving the scratch resistance of Gorilla Glass Victus.

08:31 EST Cellectar Biosciences appoints Lea as Chief Commercial Officer - Cellectar Biosciences (CLRB) announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology. In his most recent role as senior vice president hematology at TG Therapeutics (TGTX), he oversaw the sales, marketing and analytics teams for the hematology franchise.

08:26 EST Novo Integrated Sciences unit in consulting pact with pharma firm Sarfez - Novo Integrated Sciences, and Clinical Consultants International , a Novo wholly-owned subsidiary, announced the signing of a Consulting Agreement with Sarfez Pharmaceuticals a pharmaceutical research and development company. Dr. Joseph M. Chalil, MD, MBA, FACHE, Chief Medical Officer of Novo, stated, "Over 50% of patients with heart failure have overactive bladder problems adversely impacting their quality of life. The majority of patients with heart failure are prescribed one of three approved loop diuretics; however, patients may be exposed to worsening bladder problems due to dose adjustment risk. FDA-approved SOAANZ is a gentler loop diuretic that induces gradual and sustained diuresis for the patient over a longer period of time. Through its deep network of hospitals, physicians, and independent pharmacies for direct patient sales, CCI and the Novo team will immediately begin collaborating with Sarfez on the marketing and distribution of commercially available SOAANZ."

08:21 EST IPA unit BioStrand and BriaCell announce $500K artificial intelligence deal - ImmunoPrecise Antibodies announced that BioStrand an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement with BriaCell Therapeutics (BCTX,) a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. The collaboration will leverage BioStrand's LENSai software, built upon IPA's proprietary HYFT Universal Fingerprint technologies, and will focus on in silico antibody discovery to generate relevant clinical molecules for potential development. Under the terms of the Agreement, BioStrand and BriaCell will collaborate on the design, discovery, and development of anti-cancer antibodies. Upon successful antibody discovery, BioStrand will receive an upfront payment of $500,000, and will be eligible to receive future success-based development milestones, including those for the submission of Investigational New Drugs clinical milestone payments, and commercial royalties on net sales of products. Further terms are not disclosed. "We are very excited to begin this program with BriaCell and apply our technology to the development of biologics that may have a huge clinical impact," stated Dr. Ingrid Brands, General Manager and co-founder of BioStrand. "Shortening timelines, while also integrating as much information as possible upstream to improve the efficiency of the process, is extremely important in the development of highly targeted therapies. It is a step towards realizing our long-term vision of significantly advancing precision medicine."

08:15 EST Osisko Development announces sampling results from Trixie test mine - Osisko Development announces sampling results from its ongoing underground exploration program at its 100%-owned Trixie test mine, within the Company's wider Tintic Project, located in the historic East Tintic Mining District in central Utah, U.S.A. Chris Lodder, President of Osisko Development, commented, "Tintic continues to deliver high grade sampling results as our exploration efforts expand the area of mineralization in and around Trixie. As we continue to drive development to reach deeper levels of the mine beyond the main 625 level towards the end of 2023, we are very excited to test exploration potential of target areas located adjacent to historic mine workings that have previously not been tested to date. In addition to Trixie, our greater understanding of the controls on the various styles of precious and base metal mineralization opens up years of potential exploration growth and excitement for our shareholders."

08:14 EST BYND Cannasoft aims to enter global condom market - BYND Cannasoft Enterprises announced it is aiming to enter into the global condom market, which is expected to grow to $10.97 billion by 2030. The company intends to offer consumers a revolutionary design for sexual pleasure as it expands its patent for its EZ-G device to include an innovative double-faceted condom design. According to the patent application, the double-faceted condom will have a double pocket containing lubricant to heighten both partners' sexual pleasure. BYND Cannasoft intends to design its double-faceted condom to enhance pleasure and comfort while increasing the use of protection during sex and lowering the number of sexually transmitted infections. According to the patent application, the condom will have a double pocket that will contain a lubricant that is released evenly when used. The advantage of this type of condom is the possibility of diluting the lubricants with natural oils, such as CBD, at low concentrations. The oil will be evenly dispersed which is designed to alleviate difficulties in intimate relationships and increase pleasure for both partners.

08:12 EST 8x8 terminates CEO Dave Sipes, Samuel Wilson named interim CEO - 8x8 announced the following leadership changes, effective immediately: Samuel Wilson, most recently the company's CFO, has been appointed interim CEO by the board. Wilson succeeds Dave Sipes, whose employment relationship with the company as chief executive officer has been terminated effective as of November 30. Kevin Kraus, most recently the senior VP of finance at the company, has been appointed as interim CFO. The board has initiated a process to identify a permanent CEO and CFO, which will include both internal and external candidates. Separately, Laurence Denny, formerly chief compliance officer, deputy general counsel, and assistant corporate secretary, has been promoted to chief legal officer and corporate secretary effective December 9, succeeding Matthew Zinn. Zinn has informed the board that he is resigning, effective December 9 to accept the position of chief legal officer at another publicly traded company in an unrelated industry.

08:11 EST WISeKey to host array of NFT interactions at Miami Art Week - WISeKey International Holding announced that international artists have joined its WISe.ART NFT Marketplace. WISe.ART NFT Marketplace increasingly see a future for the tokens that upends the economics of content creation and influence on the internet. The WISe.ART team is the ART MIAMI, SCOPE, ARTBASEL AND DCENTRAL this week attending conferences and events to scout for new material and inform major collectors of the importance of NFTs for their existing collection and new acquisitions in digital art.

08:11 EST Janus Henderson names Michelle Dunstan Chief Responsibility Officer - Janus Henderson Group (JHG) announces the appointment of Michelle Dunstan as Chief Responsibility Officer. Joining on 9 January 2023, Michelle will be responsible for overseeing Janus Henderson's corporate responsibility and responsible investing efforts. She will be based in the US and report to Ali Dibadj, Janus Henderson's Chief Executive Officer. Michelle joins Janus Henderson from AllianceBernstein (AB), where she has spent the last eighteen years in a variety of roles, including as global equities Portfolio Manager and Senior Research Analyst, and most recently as Chief Responsibility Officer. In that role, she developed and maintained AllianceBernstein's Corporate Environmental, Social, and Governance strategy, and co-created and co-managed one of their ESG-focused equity portfolios. In a former role, Michelle devised AllianceBernstein's Responsibility policies, where she steered their ESG governance strategy, ESG integration process, engagement escalation, and stewardship policies.

08:10 EST Freshworks appoints Jason Loomis as CISO - Freshworks announced the appointment of Jason Loomis as Chief Information Security Officer. With this appointment, the company bolsters its senior technical leadership as it continues to put the power of software back in the people's hands with applications easy enough for everyone to use. Jason brings more than 20 years of experience in information technology and cybersecurity leadership to the role, most recently serving as the Chief Information Security Officer at MINDBODY, Inc., overseeing an enterprise-wide information security program and leading a globally-dispersed team.

08:09 EST Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007 - Erasca announced a clinical trial collaboration and supply agreement, CTCSA, with Pierre Fabre for the BRAF inhibitor encorafenib within key international territories. This agreement will support a clinical proof-of-concept trial evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the anti-EGFR antibody cetuximab for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer. This combination is being investigated as part of the ongoing Phase 1b/2 HERKULES-3 master protocol in patients with gastrointestinal malignancies. Erasca will sponsor the trial, and Pierre Fabre will supply encorafenib in the Pierre Fabre territories which include Europe and Asia Pacific. "We are excited to work with Pierre Fabre, a leader in precision oncology, on an international collaboration to explore ERAS-007 in combination with encorafenib and cetuximab in BRAF mCRC," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "This partnership complements our existing CTCSA with Pfizer for encorafenib within the United States and other markets. Resistance mechanisms, particularly through MAPK reactivation, limit long-term benefit with current standard of care BRAF-targeted treatments. By blocking RAS/MAPK pathway signaling at the most distal node, ERK1/2, ERAS-007 can potentially prevent pathway reactivation."

08:07 EST Harrow Health expands product supply pact with iOR Partners' - Harrow jointly announced the expansion of their national product supply agreement to provide Harrow's entire formulary compounded ophthalmic products to iOR Partners' expanding office-based surgery locations across the United States."We are thrilled to be working alongside iOR Partners as they mobilize an increasing number of cataract surgeons to perform surgery in an office-based environment, offering more personalized care in a patient-friendly setting," said Mark L. Baum, Chairman and CEO of Harrow. "iOR Partners assists practices nationwide to make office-based ophthalmic surgery a reality. Our mission has always focused on making medications accessible and affordable, and working with iOR Partners, the national leader in this fast-growing area of ophthalmic surgery, represents an important and growing channel for Harrow to meet our mission."

08:07 EST Enphase Energy launches IQ8 microinverters in France, Netherlands - Enphase Energy announced the launch of IQ8 Microinverters in France and the Netherlands, marking the first expansion into international markets for the product since its successful launch in North America late last year. IQ8 Microinverters are the smartest, most powerful microinverters yet for Enphase, with a 97.2 percent efficiency score based on European Union efficiency standards. IQ8 Microinverters are designed to match the latest generation of high output solar modules, delivering superior reliability, safety, and quality for residential solar systems. "We're pleased to be working with world-class installers in France and the Netherlands, helping us meet the growing demand for clean, reliable, and affordable energy in Europe," said Dave Ranhoff, chief commercial officer at Enphase Energy. "As Enphase continues to expand in the European solar market, we will look to enable our growth with best-in-class technology like IQ8 Microinverters and a continued focus on superior customer service."

08:05 EST Kintara Therapeutics regains compliance with Nasdaq listing rules - Kintara Therapeutics announced that the Company has received formal notice from The Nasdaq Stock Market stating that the Company has regained compliance with the minimum bid price requirement. The notice the Company received from Nasdaq on November 29, 2022 noted that the Company evidenced a closing bid price of its shares of common stock at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days.

08:05 EST Harsco signs five-year extension contract with Tata Steel - Harsco Corporation announced that its Harsco Environmental division has renewed its contract with Tata Steel at the Port Talbot steelworks for a period of five years starting July 1, 2022. Tata Steel is the UK's largest steel producer. Harsco has been providing critical services, including metal recovery, scrap processing, slag handling and BOS services at Port Talbot for more than 40 years. With an annual UK steel production of more than 3 million tonnes, Tata Steel supplies steel products to customers throughout the United Kingdom, mainland Europe and beyond. Over the next five years, Harsco Environmental will support Tata Steel's transformation project to decarbonise its operations. Tata Steel's UK business has an ambition to achieve CO2 neutral steel making by 2045 and achieving at least a 30% reduction in CO2 emissions by 2030. Harsco will continue to work with Tata Steel on several continuous improvement initiatives and collaborate on the ongoing transformation project.

08:03 EST Nuwellis receives 180-day extension to meet Nasdaq minimum bid price rule - Nuwellis announced it received an extension of 180 calendar days from the Nasdaq Stock Market to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, following the expiration of the initial 180 calendar days period to regain compliance on November 28, 2022. As a result of the extension, the Company now has until May 29, 2023 to regain compliance with the Bid Price Requirement. If at any time before May 29, 2023, the bid price of the Company's common shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it has achieved compliance with the Bid Price Requirement. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's shares, which will continue to trade on the Nasdaq Capital Market under the symbol "NUWE".

08:03 EST Petco announces partnership with Stella & Chewy's - Petco Health announced a partnership with Stella & Chewy's that will bring the brand's raw and natural food products to Petco pet care centers, petco.com and the Petco app in January 2023. An advocate of healthy pet food since its founding in 2003, Stella & Chewy's is the category leader in the raw pet food space, and this expansion helps ensure that more pet parents will have access to the benefits of raw food as part of Petco's curated assortment of high-quality nutrition without artificial ingredients.

08:02 EST PowerFleet announces launch of Powerfleet Unity - Powerfleet announced the launch of Powerfleet Unity, a new fleet intelligence platform that unites people, assets, and data together to transform the way its customers do business. The Powerfleet Unity platform enables rapid and deep integration with IoT devices and third-party business systems to a highly scalable data pipeline that powers artificial intelligence-driven insights to help companies save lives, time, and money. Powerfleet Unity's extensive integration library of data sensory device types coupled with Powerfleet's modular, business performance improvement solutions allow customers to receive rapid speed to value and deliver dramatic positive change to their business.

07:58 EST Petco jumps 13% to $10.76 after Q3 results, FY22 guidance

07:50 EST DoorDash reducing corporate headcount by approximately 1,250 people - Earlier today, Tony Xu shared the following with DoorDash employees: "This is the most difficult change to DoorDash that I've had to announce in our almost 10-year history. Today, we are reducing our corporate headcount by approximately 1250 people and saying goodbye to many talented teammates. If you are among those impacted, I am truly sorry and I apologize to have some of you wake up to this news as opposed to reading it during more normal hours. I know that for many of you, today's news will come as a shock, especially because our business remains strong and continues to grow. That is why I think it is important that I explain how I arrived at this decision, what we are doing for those departing DoorDash, and why I'm optimistic about our future." Reference Link

07:33 EST NFI Group receives order for 473 low-, zero- emission buses from San Diego MTS - NFI Group announced that its subsidiary New Flyer of America has received new firm orders for 41 transit buses from the San Diego Metropolitan Transit System, MTS, with options for up to an additional 432 buses. In total, NFI will add 617 Equivalent Units, EUs, to its backlog from firm and option orders. These units were included in NFI's pending awards at the end of the third quarter of 2022. The firm orders include: 28 Xcelsior compressed natural gas forty-foot, heavy-duty transit buses, and 13 Xcelsior CHARGE NG battery-electric forty-foot, heavy-duty transit buses. The five-year contract includes options to purchase forty-foot and sixty-foot Xcelsior CNG buses, as well as forty-foot and sixty-foot Xcelsior CHARGE NG battery-electric buses. Supported by Federal Transit Administration funds, this order will help MTS meet its goal of transitioning to a zero-emission fleet, which is outlined in its multi-year "Zero-Emission Bus Rollout Plan". In addition, the purchase will deliver on the California Air Resources Board's Innovative Clean Transit regulation, requiring agencies to transition to 100% ZEB fleets by 2040.

07:32 EST Corteva to acquire Stoller Group for $1.2B - Corteva and Stoller Group announced that Corteva has signed a definitive agreement to acquire Houston-based Stoller, one of the largest independent Biologicals companies in the industry. With operations and sales in more than 60 countries and 2022 forecasted revenues of more than $400M, Stoller brings immediate scale and profitability, with EBITDA margins that will be accretive to Corteva. The acquisition of Stoller reinforces Corteva's commitment to providing farmers with Biological tools that complement evolving farming practices and help them meet changing market expectations. The Stoller purchase price of $1.2B in cash represents an enterprise value multiple of approximately 12x based on Stoller's expected EBITDA for 2022 on a stand-alone basis. The purchase price will be paid at closing, which is anticipated to be completed in the first half of 2023 following regulatory approvals and satisfaction of customary closing conditions. The Company expects that Stoller results will be accretive to both Operating EBITDA and Operating EPS for 2023.

07:31 EST Draganfly's Vital Intelligence Technology selected by CorrecTek - Draganfly announces its Vital Intelligence Technology has been integrated with CorrecTek's Corrections Management Platform. Draganfly's Vital Intelligence Technology is designed to work both from Drones for public safety applications, and from other camera systems, to measure human vital signs in real-time. The integration of Draganfly's Vital Intelligence Technology into CorrecTek's platform can provide a cost-saving solution that can improve operational insight, workflows, overall safety, and time management. "We are very excited to integrate our Vital Intelligence Technology into CorrecTek's platform, which is used in over 200 correctional institutions and growing across the United States," said Cameron Chell, President and CEO of Draganfly. "This critical platform can help improve current intake procedures and provide valuable insight, all while helping provide a safe environment for everyone."

07:23 EST Mindset Pharma CEO Lanthier issues letter to shareholders - Mindset Pharma issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset. "As we approach the end of 2022, I would like to take a moment to remind both shareholders and the broader investment community of Mindset's recent accomplishments since our last update and express our excitement for 2023 and beyond... All of our hard work has set the stage for Mindset to launch one or more of our novel drug candidates to first in-human clinical trials in 2023... MSP-1014 is a novel and patent pending rapidly metabolized prodrug of psilocin, the active metabolite of psilocybin, and is likely to exert similar efficacy to psilocybin in improving symptoms of depression in difficult to treat patient populations... In September, Mindset received positive Scientific Advice from the UK Medicines and Healthcare products Regulatory Agency on a range of points to finalize its first-in-human clinical trial plan evaluating its lead psychedelic drug candidate MSP-1014 for the treatment of Major Depressive Disorder. This guidance will enable Mindset to significantly reduce the time and expense to progress to human clinical trials, bypassing additional preclinical safety studies usually necessary for this clinical transition, and allowing Mindset to proceed directly to treating patients... Mindset's "Family 2" of novel drug candidates are characterized by a stronger effect size compared to psilocybin and the preclinical data collectively suggest a shorter effect duration than psilocybin. After extensive preclinical screening studies, a lead drug candidate, MSP-2020, and a back-up drug candidate, MSP-2003, were selected from Mindset's Family 2 program in October and advanced to IND-enabling studies with a leading global Contract Research Organization, representing a significant milestone in Family 2's development program for the Company and its shareholders... Mindset has an unmatched track record of strategically partnering with organizations that can help us advance and commercialize our innovations. Adding to our existing partnership with Otsuka's MSRD, in September, Mindset announced an an exclusive licensing agreement with Cybin... Complementing its new drug programs, Mindset has also developed a patent pending novel cost-effective manufacturing process to synthesize psilocybin. Mindset recently completed a large batch of cGMP psilocybin with a leading international CDMO. In November, Mindset entered into an exclusive sales agreement with PharmAla Biotech Holdings... We have intentionally expanded our discovery efforts beyond tryptamines and into new, innovative distinct chemical structures. These non-tryptamine drug classes are classified as Families 6, 7, and 8 and these families are showing promising preliminary results, thus far. Over the past few years, we have developed a rich pipeline of both tryptamine and non-tryptamine drug classes... Presently, Mindset's IP portfolio encompasses 15 patents and patent applications. In September, Mindset filed an additional 16 different national applications... Our recent achievements position Mindset for an even more exciting 2023 as we continue to make tremendous progress towards our ultimate goal of getting optimized drugs to patients."

07:21 EST Sterling Check announces $700M credit facility, $100M share repurchase program - Sterling Check announced a $700M refinancing of the Company's credit facility and the authorization of a $100M share repurchase program. These distinct yet complementary strategic initiatives will enhance Sterling's financial position and flexibility by optimizing the Company's capital structure and allocation capacity. Sterling completed a refinancing of its existing debt via a $300M Term Loan A Facility and a $400M Revolving Credit Facility. The new structure extends the Company's debt maturity profile to November 2027, increases the Company's credit capacity, and is expected to reduce the Company's annual interest expense. The Company's total debt and net leverage are unchanged as a result of the transaction. Interest on the new credit facility will be based on a Total Net Leverage grid and will initially bear interest at the Secured Overnight Financing Rate plus a credit spread adjustment plus 2.25%. In the near term, Sterling plans to enter into an interest rate hedging arrangement to substantially fix the facility's interest rate. Sterling's Board of Directors also authorized the repurchase of up to $100M of the Company's shares over a period through December 31, 2024. The program is expected to be funded through the Company's existing cash and future free cash flow. It will be executed on a discretionary basis through open market repurchases, private transactions, or other transactions, including through block trades and Rule 10b5-1 trading plans. Share repurchases under the program will be consistent with the Company's strategic initiatives prioritizing investments in organic and acquisitive growth. The Company is not obligated to repurchase any specific number of shares, and the timing and amount of any share repurchases will be subject to several factors including share price, trading volume, market conditions, and capital allocation priorities. The share repurchase program may be suspended, terminated or modified without notice at any time.

07:18 EST BioXcel announces first patients dosed in SERENITY III Phase 3 trial - BioXcel Therapeutics announced that the first 13 patients have been dosed in Part 1 of the pivotal Phase 3 SERENITY III trial investigating at-home use of BXCL501 sublingual film, the Company's proprietary, orally dissolving film, for agitation associated with bipolar I or II disorder or schizophrenia. "Evaluating BXCL501 for at-home use is an exciting and important milestone that potentially expands the market opportunity for the treatment of agitation and drives the growth of our neuroscience franchise," said Robert Risinger, M.D., Chief Medical Officer, Neuroscience of BioXcel Therapeutics. "We anticipate top-line data from SERENITY III as well as our TRANQUILITY II trial for Alzheimer's-related agitation in the first half of 2023."

07:17 EST Optinose extends expected cash runway beyond PDUFA data for XHANCE - Optinose provided corporate updates and announced that CEO Peter Miller will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. "The addition of cash from the recent financing and the amendment of our note purchase agreement with Pharmakon enable our organization to focus on XHANCE growth and the submission of a supplemental NDA in early 2023," stated CEO Peter Miller. "We believe chronic sinusitis is an enormous opportunity relative to our current business with up to 10 times the number of diagnosed patients versus our current nasal polyps indication - many of whom are treated by the same physicians we call on today. We believe a first-ever approval in chronic sinusitis would be a significant advancement in care for patients and represents a valuable opportunity for our specialty business and a potential partner in primary care." On November 23, 2022, the Company's previously announced common stock and warrant financing closed resulting in approximately $50.0 million of gross proceeds to the Company, prior to deducting underwriting discounts and commissions and expenses payable by the Company. The Company expects that its current cash and cash equivalents will be sufficient to fund its operations and debt service obligations through the expected PDUFA action date for XHANCE as a treatment for chronic sinusitis in the fourth quarter of 2023. Concurrent with the financing, the Company amended and restated its note purchase agreement with Pharmakon. The amended and restated agreement extends the interest only period from September 30, 2023 to September 30, 2025, extends the maturity date from September 30, 2024 to June 30, 2027, modifies the financial covenant requiring the Company to achieve minimum trailing twelve-month consolidated XHANCE net product sales and royalties, and modifies certain other terms.

07:17 EST AC Immune's ACI-35.030 selected for further development - AC Immune (ACIU) announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau vaccine candidate, has been selected for further development. The ACI-35.030 anti-pTau vaccine candidate is being developed in collaboration with Janssen Pharmaceuticals, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments species, both of which are closely implicated in Alzheimer's disease. The excellent performance of ACI-35.030 in the trial participants potentially opens promising avenues for AD treatment and prevention, which could offer an important societal impact. We thank the team at Janssen for their contributions of valuable knowledge, expertise, and resources to support this collaboration." The selection of ACI-35.030 is supported by new clinical data from the Phase 1b/2a trial presented at the Clinical Trials on Alzheimer's Disease Conference 2022. The vaccine candidate was generally well tolerated.

07:15 EST Aridis Pharmaceuticals closes patient enrollment in Phase 2a study of AR-501 - Aridis Pharmaceuticals announced the closing of patient enrollment in the multiple ascending dose and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in cystic fibrosis patients. The Company is on track to complete database lock, data analyses, and disclose top-line data in the first quarter of 2023. The Phase 2a study enrolled 39 CF patients from 24 clinical centers in the US. The CF patients were randomized and treated in 4 cohorts; 3 cohorts received three weekly multiple ascending doses of active drug at 6.4 mg, 20 mg and 40 mg or placebo, while the 4th Cohort being dose-ranging with subjects randomized to three weekly doses of AR-501 6.4 mg, 20 mg, or 40 mg, or placebo. CF subjects were followed for 28 days after last study dose for safety and pharmacokinetics of inhaled AR-501. Aridis previously reported positive Phase 1 safety data in June 2020 in healthy adults who were exposed to either a single ascending dose regimen or a multiple ascending dose regimen. "We worked diligently through the pandemic to enroll patients and are very pleased to reach this key milestone for our Phase 2a study of AR-501 in CF patients." commented Aridis' Chief Medical Officer Hasan Jafri, MD. "Our focus is now on data gathering from the clinical trial centers. We anticipate reporting top-line results in the first quarter of 2023."

07:13 EST Bluebird Bio to sell Zynteglo PRV for $102M - Bluebird Bio announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher, or PRV, for $102M. Bluebird was granted two PRVs upon the FDA approvals of Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and Skysona for the treatment of early, active cerebral adrenoleukodystrophy, on August 17 and September 16 respectively. Bluebird will receive a payment of $102M upon closing of the transaction, which remains subject to customary closing conditions, including anti-trust review. The company continues to explore additional financing opportunities, including the monetization of its second PRV, and anticipates providing full year 2023 guidance early next year.

07:12 EST Freight Technologies collaborates with University in Mexico - Freight Technologies expands its training program, Fr8University, by directly collaborating with one of the most prestigious private Universities in Mexico. Fr8University, an educational program offering classroom and on-the-job training for incoming Fr8Tech team members and university students, was started in late 2020 and matriculated its first graduating class in early 2021. Fr8University is now moving beyond training and hiring students by directly entering into a collaborative agreement with a leading University in Mexico to secure the company's access to talent with the view to ensuring continuity in the Company's growth as well as providing academia with access to real-time business experiences and technology development challenges.

07:11 EST Enbridge, OLCV to develop CO2 sequestration hub in Texas Gulf Coast - Enbridge (ENB) and Oxy Low Carbon Ventures, a subsidiary of Occidental (OXY), announced that the parties intend to work towards jointly developing a carbon dioxide sequestration hub in the Corpus Christi area of the Texas Gulf Coast. Enbridge and OLCV signed a letter of intent to explore this joint project, which would provide a complete CO2 solution for area emitters through the development of a pipeline transportation system and sequestration facility. Enbridge and OLCV would leverage each company's strengths to advance the development of a sequestration hub and associated transportation infrastructure. Enbridge would develop, construct, and operate the pipeline facilities and OLCV would develop, construct, and operate the sequestration facilities. The hub is expected to provide CO2 solutions for Enbridge's proposed facilities as well as other point source emitters in the Corpus Christi area. Enbridge and OLCV would jointly market the CO2 pipeline transportation and sequestration services to other third-party CO2 point source emitters in the Ingleside and Corpus Christi areas.

07:10 EST First Wave files IND for microgranule delivery formulation of adrulipase - First Wave BioPharma announced that it has submitted an Investigational New Drug, IND, application seeking authorization from the U.S. Food and Drug Administration, FDA, to evaluate an enhanced enteric microgranule delivery formulation of adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis in human clinical trials. Upon IND clearance, First Wave expects to initiate a Phase 2 trial at the beginning of 2023. "Filing the IND is an important step in enabling First Wave to initiate the planned Phase 2 trial of our new formulation for adrulipase," said James Sapirstein, President and CEO of First Wave BioPharma. "If the FDA grants authorization in the next 30 days, we expect to start the study in early 2023 with topline data anticipated towards the end of the first half of 2023. We anticipate that these near-term clinical milestones will reinforce our previous research, such as data recently presented at AAPS 2022 showing the new adrulipase formulation can deliver the drug in the intended area of the gastrointestinal tract, where it can provide the desired therapeutic effect," Sapirstein added. "We look forward to investigating this potential in a Phase 2 clinical trial and the opportunity to one day provide therapeutic relief to patients with exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis."

07:09 EST Enbridge expects to deploy approximately C$6B of capital in 2023 - Enbridge expects to deploy approximately C$6B of capital in 2023, inclusive of maintenance capital. The balance sheet will remain strong with the Debt-to-EBITDA ratio at the end of 2023 expected to be in the lower half of the company's 4.5-5.0x target range. The financing plan includes issuances of approximately C$6B in incremental debt in 2023, net of maturities, with no external equity required. The company has hedged over half of its anticipated fixed-rate term-debt issuances for 2023. Enbridge intends to re-file a normal course issuer bid before year end to repurchase up to C$1.5B of its common shares. This provides Enbridge with the capital allocation flexibility to opportunistically return capital to shareholders through repurchases, while maintaining focus on growing per share earnings and DCF.

07:08 EST AnPac Bio regains complaince with Nasdaq listing requirement - AnPac Bio-Medical Science announced that the company has been notified by the Office of the General Counsel of The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1 per share bid price requirement of Listed Securities required for continued listing as set forth in Listing Rule 5450(a)(1). The Company will remain under the Mandatory Panel Monitor until June 9, 2023, imposed by a previous Hearings Panel's decision on June 9, 2022.

07:07 EST Climb Channel Solutions selects TeamViewer as preferred partner - Climb Channel Solutions (CLMB) has selected TeamViewer (TMVWY) as their preferred partner for providing remote access and support solutions for customers around the world. The extension of the longstanding partnership between Climb and TeamViewer leverages Climb's strong global network of reseller partners and TeamViewer's leadership in remote connectivity, to jointly offer more organizations the ability to work from anywhere, with access to any device, providing instant remote support for customers and employees.

07:05 EST Transcode Therapeutics announces eIND submission to U.S. FDA - TransCode Therapeutics announced that it has submitted an exploratory Investigational New Drug, eIND, application to the U.S. Food and Drug Administration, FDA, for a planned First-in-Human Phase 0 clinical trial. The planned clinical trial is to evaluate TransCode's lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers. "We are very excited to take this next step in the development of TTX-MC138 which we hope will bring us closer to introducing this first of its kind treatment for metastatic disease," said TransCode's Chief Executive Officer and co-founder, Michael Dudley. "We are hopeful that the study conducted under the eIND will demonstrate successful delivery of our lead therapeutic candidate to metastatic lesions in patients with advanced solid tumors. The delivery of oligonucleotide therapeutics to sites other than the liver has remained a significant challenge for decades. Overcoming this challenge would represent an unprecedented step in unlocking therapeutic access to a variety of well documented genetic targets involved in a range of cancers and beyond." The company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. A Phase 0 clinical trial is an exploratory study conducted under an Investigational New Drug application. Exploratory IND studies usually involve very limited human exposure to a therapeutic candidate; their primary purpose is to evaluate the candidate's safety and mechanism of action. In TransCode's planned clinical trial, up to 12 patients will be given a single dose of radiolabeled TTX-MC138 followed by noninvasive positron emission tomography-magnetic resonance imaging.

07:05 EST Enbridge raises quarterly dividend 3.2% to C$0.8875 per share - Payable on March 1, 2023 to shareholders of record on February 15, 2023.

07:02 EST Aeglea BioTherapeutics names Jeffrey Goldberg as CEO - Aeglea BioTherapeutics announced the appointment of Jeffrey Goldberg as president, CEO and member of the board of directors effective November 29. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and CEO of Immunitas Therapeutics.

07:01 EST Brown Brothers Harriman, State Street terminate transaction - Brown Brothers Harriman announced that it has mutually agreed with State Street to terminate the agreement to sell its Investor Services business to State Street. BBH made this decision after it became clear that State Street will be unable to obtain necessary approvals from its regulators for the agreed transaction.

07:00 EST Chunghwa Telecom responds to union call for overall wage increases - Chunghwa Telecom announced that it has engaged in talks with the Chunghwa Telecom Workers' Union on November 21 to respond to their call for comprehensive salary increases. The company said that it will take the economic uncertainty and the actual operating results of year 2022 into consideration in deciding the extent of wage increases and make an announcement at a proper time. The company said, "Chunghwa Telecom stated that the Company has its internal policies for annual salary increments on the basis of individual assessment, and carries out comprehensive wage increases from time to time based on operating performance and market conditions. In January of 2022, the Company made an announcement to raise overall salaries by 4% in response to a more challenging economic environment as well as offer a one-time encouragement bonus to staff members in recognition of staff contribution to outperforming operating results in 2021. Prior to that, the Company also raised overall salaries by 3% to 5% in 2020 for talent retention. Chunghwa said the recent salary increases had demonstrated its willingness to share operating success with employees and place great emphasis on employees' salaries and benefits. Chunghwa further highlighted its competitive compensation scheme in the telecom industry of Taiwan. According to an analysis of the average salary of publicly traded companies published by the Taiwan Stock Exchange, the average salary of Chunghwa's non-managerial full-time staff in 2021 was ahead of its peers. In addition to pay scheme, Chunghwa commits to staff's welfare and offering a favorable work and family balance environment for all employees. Consequently, the Company has launched a variety of employee benefits plan over time. In 2022, the Company has offered to establish 9 workplace teaching and care centers with 16 classes in six cities in Taiwan in order to enhance mutual care at the workplace, which allow employees to look after their families while working. Moreover, the Company provides employees with more benefits than what the government stipulates. For example, Chunghwa led by initiating a program that allows employees with children under the age of three years old to work one hour less per day. The Company has also increased paternity and maternity leave to 10 days from 7 days in which the government requires. Recently, the Company announced a raise to the maternity pension per child to NTD 20,000 in 2023, as well as a raise in the monthly subsidy to employees with children between the ages of 0-6 to NTD 1,000 per month. Due to its commitments and practices, the Company had won recognitions and awards for its pioneered initiatives during the year. Notably, "The World's Top Female-Friendly Companies 2022 Survey" released by Forbes has ranked Chunghwa Telecom the sixth leading telecom service and cable companies in the world in terms of establishing a female-friendly workplace."

06:52 EST Sanofi reports Phase II/III study results for acoziborole published in Lancet - The Drugs for Neglected Diseases initiative, or DNDi, and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, an investigational treatment for sleeping sickness, published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo and Guinea. "Between 2016 and 2019, DNDi and its partners led an open-label, Phase II/III study to assess the safety and efficacy of acoziborole in patients with early- and late-stage g-HAT. 208 patients were recruited at 10 hospitals in the DRC and Guinea. The 18-month treatment success rate for acoziborole was 95% in late-stage g-HAT patients, corresponding to the best results from studies with existing treatments of 94%. In addition, 100% of the 41 patients with early-stage g-HAT were considered as treatment successes at all timepoints. The study shows that acoziborole has a favourable safety profile, with no significant drug-related safety signals reported. These pivotal results will form the basis of Sanofi's dossier submission to the European Medicines Agency (EMA) and represent another milestone in the quest to eliminate sleeping sickness. Upon the EMA's positive opinion and local approval, Sanofi will donate acoziborole to the WHO through its philanthropic organization, Foundation S - The Sanofi Collective. Acoziborole is currently under clinical investigation and its safety and efficacy have not been evaluated by any regulatory authority," the company stated.

06:49 EST State Street to terminate deal to buy BBH's Investor Services business

06:30 EST AstraZeneca to present haematology portfolio and pipeline at ASH 2022 - The company states: "AstraZeneca will present 47 abstracts showcasing new data from across its haematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology Annual Meeting and Exposition, 10 to 13 December 2022. A total of eight approved and potential new medicines will be featured across more than ten types of blood cancers and rare diseases, including data in chronic lymphocytic leukaemia, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome and amyloid light chain amyloidosis." Reference Link

06:15 EST Argenx to acquire PRV for $102M - Argenx announced an agreement to acquire a FDA Priority Review Voucher, or PRV, for $102M. A PRV entitles the holder to FDA priority review of a single biologics license application, or BLA, which reduces the target review period and may lead to an expedited approval. Argenx expects to redeem the PRV for a future marketing application for efgartigimod, its first-in-class neonatal Fc receptor blocker.

06:07 EST Equinix announces $40M investment in Malaysia - Equinix announced its market entry into Malaysia with plans to build a new International Business Exchange data center located in Johor, called JH1. With an initial investment of approximately $40M, JH1 is scheduled to begin operations in Q1 2024, providing 500 cabinets and 1,960 square meters of colocation space. The IBX data center will support Malaysian companies and multinationals doing business in Malaysia with access to Platform Equinix to bring together and interconnect the foundational digital infrastructure that powers their success. Malaysia's digital economy is forecast to reach $34B in Gross Merchandise Value by 2025 with the country on course to achieve a digital economy contribution to Gross Domestic Product of at least 25.5% the same year. Equinix's expansion in Malaysia will unlock opportunities for Malaysian businesses expanding internationally and for multinational corporations pursuing growth and innovation in the Malaysian market. Malaysian companies will benefit from the ability to accelerate their evolution from traditional to digital businesses by rapidly scaling their infrastructure, easily adopting hybrid multicloud architectures and interconnecting with strategic business partners within the Platform Equinix ecosystem of more than 10,000 customers.

05:53 EST Stellantis, Banco Santander to reorganize automotive financing partnership - Stellantis (STLA) and Banco Santander (SAN) have agreed to reorganize their automotive financing partnership in Brazil. The contract signed with Banco Santander Brasil S.A. includes: the purchase by Banque PSA Finance S.A. of 50% of the shares in Banco PSA Finance Brasil S.A., a joint venture which was held 50/50 by a subsidiary of Banco Santander Brasil and Banque PSA Finance S.A. The purchase by Stellantis Services of 50% of the shares in PSA Corretora de Seguros e Services Ltd, a joint venture held 50/50 by Banco Santander Brasil and Stellantis Services. The completion of the transactions will be subject to the fulfillment of certain suspensive conditions usual in similar transactions, including obtaining the relevant regulatory authorizations. Upon completion, Banque PSA S.A. will become the sole shareholder of Banco PSA Finance Brasil and Stellantis Services will be the sole shareholder of PSA Corretora.

05:22 EST Regal Rexnord to explore alternatives for global motors, generators business - Regal Rexnord announced that it intends to explore strategic alternatives for the global motors and generators businesses that represent a majority of the sales within its Industrial Systems reporting segment. The strategic review may or may not lead to a decision to divest these businesses. Regarding the announcement, CEO Louis Pinkham commented, "I am proud of what our Industrial team has accomplished in the last few years. Through their disciplined deployment of 80/20 and rigorous use of lean tools, adjusted EBITDA margins for the business have improved by roughly 700 basis points. The business is also growing nicely, aided by share gains, which is evident in recent revenue and orders performance. Now, after carefully considering for some time how best to help the Industrial Systems business maximize its potential, we decided to explore whether there might be a better owner of these assets, in particular our global motors and generators businesses. It is in this spirit that we're launching the strategic review announced today. We plan to review our findings in a disciplined and rational manner, and after sharing conclusions with our associates, make them known to other relevant stakeholders."